Cantor maintains Intellia stock at $65 target despite trial concern

On Thursday, Intellia Therapeutics (NASDAQ:NTLA) shares fell sharply in post-market trading following a disclosure related to its ongoing Phase 3 MAGNITUDE study. The company, currently valued at $1 billion with shares trading at $9.66, reported through an 8-K filing that a patient had experienced asymptomatic Grade 4 elevations in liver transaminases. This condition occurred during a trial that is assessing nex-z as a one-time treatment for transthyretin cardiomyopathy (TTR-CM), a progressive heart disease. According to InvestingPro data, the stock has shown significant volatility with a beta of 2.33, making it more than twice as reactive to market movements as the average stock.

Despite the negative market reaction, which saw Intellia stock plunge by approximately 17%, analysts at Cantor Fitzgerald have maintained their Overweight rating and a $65.00 price target on the stock. This target aligns with the broader analyst community’s positive outlook, as revealed by InvestingPro data showing analyst targets ranging from $8 to $106, with 13 analysts recently revising their earnings estimates upward. The firm’s analyst commented on the situation, suggesting that the market’s response might be an overreaction. The analyst stated, "After market close today, NTLA disclosed (through an 8-K filing) that a patient in the Phase 3 MAGNITUDE study experienced asymptomatic Grade 4 elevations in liver transaminases... we don’t think it’s quite time to panic yet, and see the sharp move as an overreaction."

The MAGNITUDE study is a critical component of Intellia’s efforts to develop treatments for TTR-CM, with nex-z being a potentially transformative therapy for patients suffering from this condition. The study’s results are highly anticipated as they could have significant implications for the company’s product pipeline and future revenue streams.

The recent event highlights the inherent risks associated with clinical trials, especially in the later stages when the number of participants is higher and the treatments are closer to potential commercialization. Such developments are closely monitored by investors and analysts alike, as they can have immediate and profound effects on a company’s stock performance.

Intellia Therapeutics has not issued any further statements regarding the incident or its potential impact on the MAGNITUDE study’s timeline or outcomes. Market observers and stakeholders will be looking for additional information to assess the situation fully. Meanwhile, the support from Cantor Fitzgerald suggests confidence in the stock’s value and the company’s long-term prospects despite short-term volatility. InvestingPro’s Financial Health Score indicates a ’FAIR’ overall rating for the company, with strong liquidity metrics showing current assets at 4.9 times short-term obligations. Investors seeking deeper insights can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, which includes detailed analysis of Intellia’s financial health, valuation metrics, and growth prospects.

In other recent news, Intellia Therapeutics reported significant progress in its Phase 3 clinical trials, with the HAELO study for NTLA-2002 on track for completion by the third quarter of 2025. The MAGNITUDE-2 study for nex-z is also advancing, targeting transthyretin amyloidosis with polyneuropathy, with a potential U.S. launch by 2029. Meanwhile, the MAGNITUDE study for ATTR cardiomyopathy has enrolled approximately 365 patients, with adverse events consistent with earlier trials. Following a safety update, H.C. Wainwright maintained its Buy rating and a $30 price target, noting the isolated nature of a liver enzyme elevation incident. BofA Securities adjusted its price target to $39, maintaining a Buy rating but expressing caution until more safety data is available. Guggenheim Securities also revised its price target to $45 while keeping a Buy rating, citing the potential market size for ATTR-CM. Citizens JMP reiterated a Market Perform rating, acknowledging the adverse event but highlighting mitigating factors. These developments reflect ongoing investor interest and scrutiny as Intellia advances its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.